Ongoing phase 3 trials target improved therapies for hematologic malignancies, focusing on CLL, multiple myeloma, and ...
Panelists discuss how advanced practice providers (APPs) coordinate the logistical aspects of anti-amyloid therapy delivery, ...
Medical expenditures were higher among individuals with a body mass index (BMI) outside the “healthy weight” range, reflecting the broader health burden associated with both low and high BMI, ...
Panelists discuss how APPs facilitate efficient Alzheimer treatment timelines through proactive coordination. Panelists discuss how initiating Alzheimer therapy demands precise timing and ...
Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces ...
Patients with moderate to severe allergic rhinitis (AR) often experience years of uncontrolled symptoms, worsened quality of ...
A multistakeholder study explores how law enforcement presence in EDs affects survivors of violence and outlines ...
The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...
The bipartisan funding bill prevents a government shutdown, ensuring uninterrupted operations for key agencies, including HHS ...
Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...
The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival ...
Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results